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Objective: Research has reported associations among selected genetic susceptibility
biomarkers and risk of (a) normal cognitive aging decrements, (b) established mild
cognitive impairment (MCI), and (c) sporadic Alzheimer’s disease (AD). In focusing on the
transitional normal-to-early MCI phase, we examine associations among three theoretically
relevant polymorphisms (APOE [rs429358, rs7412], BDNF [rs6265], COMT [rs4680]) and
both baseline cognitive status (MCI vs. normal aging) and two-wave (four-year) longitudinal
stability or change profiles. The latter included three profiles: (a) stable as normal
aging, (b) stable or chronic impairment (MCI-to-MCI), and (c) emergence of impairment
(normal-to-MCI).
Method: Genotyped older adults (n = 237 at baseline; age range = 64–91; 62% women)
from the Victoria Longitudinal Study were examined for (a) independent and interactive
associations of three genetic polymorphisms with (b) two objectively classified cognitive
status groups (not-impaired controls (NIC) and MCI) at (c) both baseline and across a
two-wave (four-year) longitudinal interval.
Results: First, logistic regression revealed that the presence of at least one APOE ε4
allele (the risk factor for AD) was linked to greater baseline risk of objective MCI. Second,
multinomial logistic regression revealed that (a) the presence of an APOE ε4 allele was
associated with an increased risk of 4-year MCI status stability (chronicity), and (b) the
COMT homozygous risk genotype (G/G or Val/Val) was associated with an increased risk
of both MCI-to-MCI stability (chronicity) and emerging NIC-to-MCI conversion.
Discussion: Both chronicity and emergence of objectively classified early cognitive
impairment may be genetically heterogeneous phenomena, with influences from a panel
of both normal cognitive aging (COMT ) and AD-related (APOE) polymorphisms.
Keywords: APOE , BDNF , COMT , mild cognitive impairment, Victoria Longitudinal Study
INTRODUCTION
The often lengthy and subtle pathophysiological changes linking
normal aging and diagnosable sporadic (late-onset) Alzheimer’s
disease (AD) are continuous, differentiable, detectable, and wor-
thy of study as a classifiable phase in growing numbers of older
adults (e.g., Albert et al., 2011; McKhann et al., 2011; Sperling
et al., 2013). Known as mild cognitive impairment (MCI), the
key clinical characteristics, markers, and classification procedures
have evolved toward a cluster of shared perspectives, related
methods, and clinical health implications (e.g., Ritchie et al.,
2001; Winblad et al., 2004; Petersen and Knopman, 2006; Albert
et al., 2011; Geda and Nedelska, 2012; Lin and Neumann, 2013;
Sperling et al., 2013). Briefly, summary principles include: (a)
MCI is defined as a mild but clinically relevant neurocognitive
dysfunction emerging in a dynamic and variable distribution
between normal decline and dementia; (b) biomarkers and risk
factors for MCI-related transitions can lead to preclinical targets
for earlier interventions to prevent or delay AD; and (c) much
work is needed to classify, track, and identify markers of MCI-
related transitions (Payton, 2006; Golde et al., 2011; Abner et al.,
2012; Hurd et al., 2013; Risacher et al., 2013).
Recent research has focused on detecting biological (e.g.,
genetic risk) and environmental (e.g., lifestyle) factors that dis-
criminate cognitively normal older adults fromMCI groups (e.g.,
Woodard et al., 2012; Anstey et al., 2013). New longitudinal
data have revealed evidence of varying stabilities in status, espe-
cially in MCI transitions (e.g., Albert et al., 2011; Dolcos et al.,
2012; Risacher et al., 2013). This implies that MCI status may
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be a dynamic, heterogeneous, multi-faceted, and variable phe-
nomenon (Palmer et al., 2002; Koepsell and Monsell, 2012). By
definition, MCI involves relatively lower levels of performance
or accelerated decline—but not deficits that interfere with every-
day functioning or that merit a dementia diagnosis (Albert et al.,
2011).
Recommended longitudinal research requires several key clas-
sification elements. First, initial status assessment could be con-
firmed independently at a second session separated by a clinically
meaningful interval (e.g., Vandermorris et al., 2011). At baseline,
early or transitional MCI classifications may not be etiologically
pure, diagnostically firm, or projected to follow an inevitable path
to dementia. Second, the phenotypic heterogeneity and multidi-
rectionality of normal cognitive aging (e.g., Dixon et al., 2012;
Josefsson et al., 2012) may be reflected also in early transition
phases of MCI (Koepsell and Monsell, 2012). Third, multiple
factors (e.g., genetic, physiological, health, environmental) con-
tribute to a wide range of normal and early-impaired cognitive
aging changes (Fotuhi et al., 2009; Anstey, 2014). Fourth, markers
may be independently or interactively (e.g., synergistically) used
to discriminate normal aging and early MCI (e.g., Forlenza et al.,
2010; Lanni et al., 2012; Risacher et al., 2013). Fifth, classifying
individuals in provisional MCI status requires assessments that
(a) differentiate normal aging decrements from those prodromal
for dementia, (b) produce repeatable (stable) status over longitu-
dinal time, (c) are sensitive to early transitions that emerge during
the study period, or (d) are associated with eventual conversion to
AD or a related disorder. Finally, MCI classification schemes can
be characterized by the extent to which they fulfill these validity-
related process and outcome criteria (e.g., Gauthier et al., 2006;
Dolcos et al., 2012).
We used objective criteria to identify cognitive deficits vis-à-
vis age and education level (e.g., Ritchie et al., 2001; Dixon et al.,
2007; de Frias et al., 2009; Plassman et al., 2010; Dolcos et al.,
2012). These objective-based procedures coordinate with consen-
sus recommendations but are also transferable across research
settings, including clinics, labs, and data archives. For exam-
ple, using these objective classification procedures we found that
select functional biomarkers (e.g., blood pressure, body mass
index) could (a) differentiate not-impaired control (NIC) from
MCI groups at baseline, (b) establish high levels (70–80%) of
status and cognitive stability over a 4-year longitudinal period,
(c) provide sensitivity to subtle status transitions (de Frias et al.,
2009; Dolcos et al., 2012; Dixon and de Frias, 2014), and (d) relate
to underlying neurobiological markers via metabolomics analy-
ses (Zheng et al., 2012). Informing present research on genetic
markers of non-demented aging and MCI are studies of both
susceptibility genes for sporadic (late-onset) AD (e.g., Bertram
et al., 2007) and candidate genetic associations and interactions
(e.g., Martinez et al., 2009; Harris and Deary, 2011; Laukka et al.,
2013; Sapkota et al., 2014). Examining associations with emerg-
ing MCI is a promising research direction (Albert et al., 2011;
Brainerd et al., 2011; Izaks et al., 2011; Risacher et al., 2013;
Caselli et al., 2014). We now test the role of specific genetic mark-
ers of normal cognitive aging and AD, as they relate to early
phases of mild cognitive impairment status and change, with
the general goal of promoting early detection with its promising
intervention possibilities (Reinvang et al., 2010; Risacher et al.,
2013).
Both non-demented cognitive aging and sporadic AD are
genetically heterogeneous (Harris and Deary, 2011). Early MCI
conditions may reflect genetic influences from polymorphisms
related to both normal cognitive changes and AD outcomes.
We assembled new data from the Victoria Longitudinal Study
(VLS) to test whether three commonly associated genetic mark-
ers of normal cognitive aging or neurocognitive dysfunction are
also associated with objectively classified (a) early MCI status
(vs. non-demented aging) at baseline, (b) a 4-year MCI-related
status stability profile reflecting chronicity of impaired status,
and (c) a 4-year MCI-related status profile reflecting a tran-
sitional phase from normal aging to MCI. Three genes com-
monly implicated in aging and neurocognitive functioning are
Apolipoprotein E (APOE, rs429358 and rs7412), Brain-derived
Neurotrophic Factor (BDNF, rs6265), and Catechol-O-Methyl
Transferase (COMT, rs4680). APOE is involved in lipoprotein
metabolism. The well-known ε4 variant is the largest known
genetic risk factor of sporadic AD and has been implicated in
normal cognitive aging decline (e.g., Jorm et al., 2007; Kozauer
et al., 2008; Wisdom et al., 2011; Schiepers et al., 2012; Davies
et al., 2014). The other two alleles of APOE are ε2 and ε3, with
(a) the former considered potentially protective and (b) the latter
considered neutral for cognitive and neurodegenerative disease.
The molecular foundations of BDNF and COMT associations
with neurocognitive performance have been well-described (e.g.,
Savitz et al., 2006). Briefly, COMT codes for an enzyme that
degrades catecholamine neurotransmitters such as dopamine in
the synaptic cleft. The polymorphism is represented by a valine
(Val or G) and methionine (Met or A) substitution, with the lat-
ter reducing dopamine degradation. COMT Val carriers (both
Val-Val and Val-Met) are considered relatively at risk for specific
cognitive deficits with aging (e.g., Barnett et al., 2008; Wishart
et al., 2011) and possibly MCI (Martinez et al., 2009; Lanni et al.,
2012). BDNF is a neurotrophic factor involved in neuronal sur-
vival and plasticity. BDNF expression declines with aging and
it is associated with memory performance. The single polymor-
phism is represented by a Val andMet substitution, with the latter
associated with lower hippocampal volume and reduced mem-
ory (and cognitive) performance in aging (Miyajima et al., 2008;
Tapia-Arancibia et al., 2008), although direct associations are
inconsistent (Forlenza et al., 2010; Mandelman and Grigorenko,
2012). For BDNF, Met carriers (both A/A and A/G) are at risk.
In this study, each of the genes offered potential risk for MCI sta-
tus classification and MCI status stability over time [i.e., APOE
risk= ε4 carrier; COMT risk=Val carrier (G/G and A/G); BDNF
risk = Met carrier (A/A and A/G)].
Of the three genetic polymorphisms, APOE is the theoreti-
cally most likely associate of MCI status and stability (Brainerd
et al., 2011; Harris and Deary, 2011). Several recent studies that
linked APOE ε4 status to relatively late risk of preclinical pro-
gression to AD (e.g., Lane et al., 2008; Barabash et al., 2009;
Elias-Sonnenschein et al., 2011; Reinvang et al., 2013). Until
recently the ε4 variant (including ε4/ε4 and ε4/ε3 combinations)
has been inconsistently linked toMCI status, likely reflecting both
clinical and methodological differences in status classification
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(e.g., Brainerd et al., 2011; Risacher et al., 2013). The present
study extends a growing collection of results in several ways.
First, complementing other studies (e.g., Brainerd et al., 2011;
Anstey et al., 2013), we focus on older adults enrolled in a lon-
gitudinal study (ages 65–91 at baseline). Second, we examine
concurrent and two-wave cognitive status stability relationships.
Third, we used a standard and fully objective procedure for MCI
classification, which may be useful for detecting early preclini-
cal manifestations of impairment and potentially informative for
translational goals. Fourth, in addition to APOE, we include two
selected genetic polymorphisms, both of which are prominently
linked with cognitive phenotypes in normal aging (but rarely
with MCI) (Harris and Deary, 2011). However, both BDNF and
COMT have been reported as playing indirect or complementary
roles in some studies with implications for MCI and dementia
(e.g., Hashimoto et al., 2009; Martinez et al., 2009; Forlenza et al.,
2010; Rowe et al., 2010). It is conceivable that these two genetic
variants often associated with non-demented cognitive aging phe-
notypes may be sensitive to early cognitive changes associated
with preclinical transition processes. To our knowledge, no pre-
vious study has investigated the potential genetic links to MCI
of all three genes in the same sample, nor to the longitudinal
study of MCI status stability (normal, impairment) or instability
(emerging impairment).
We test two research questions. First, we use baseline data
to investigate whether APOE, BDNF, or COMT polymorphisms
independently or interactively differentiate between not-impaired
cognitively (NIC control group) and MCI adults. Second, using
longitudinal data, we test whether APOE, BDNF, and COMT
polymorphisms are independently or interactively associated with
stability classification. Specifically, we used the stable normal
aging two-wave combination (i.e., NIC-to-NIC) as the com-
parison for testing genetic influences on two theoretically and
clinically viable profiles of cognitive status stability: (a) the con-
version or declining status profile (NIC-to-MCI) and (b) the
stable and chronic status profile (i.e., MCI-to-MCI).
MATERIALS AND METHODS
PARTICIPANTS
This research was conducted under full, active, and continu-
ous human ethics approval from prevailing Institutional Review
Boards. Written informed consent was obtained from all par-
ticipants. Participants were community-dwelling older adults
from the Victoria Longitudinal Study (VLS), originally recruited
through advertisements in the public media and to community
groups. The VLS is an ongoing multi-sample sequential inves-
tigation of multiple aspects (e.g., cognitive, neuropsychological,
health, sensory, and biological) of human aging. Detailed back-
ground information on the design, measures, and procedures
is available (e.g., Dixon and de Frias, 2004). For this study, we
assembled a 2-wave (mean re-test interval = 4.59 years) longi-
tudinal data set by combining data collected during the same
time period across VLS Samples 1 and 2, including only partic-
ipants with genetic data. Specifically, the current Wave 1 (W1)
data were from VLS Sample 1 (Wave 5) and VLS Sample 2
(Wave 3). Similarly, the current Wave 2 (W2) data were from
VLS Sample 1 (Wave 6) and VLS Sample 2 (Wave 4). Data
were analyzed first using only W1 data (cross-sectional) and then
using the full 2-wave longitudinal design. At initial intake, VLS
exclusionary criteria are implemented for all samples in order to
establish relatively healthy cohorts of older adults, most of which
proceed to develop aging-related cognitive and physical health
conditions (Dixon and de Frias, 2004). For the present study,
exclusionary criteria at baseline (W1) included a history of AD
or any dementia, psychiatric disturbance or use of psychiatric
medication, MMSE scores less than 24, serious cardiovascular
or cerebrovascular disease conditions, uncontrolled hypertension,
Type 1 diabetes, or history of serious head injury.
The first research question required the W1 baseline sam-
ple. Of the W1 participants (n = 237), 136 met the criteria (see
below) for the NIC group (Age: M = 73.12, SD = 5.25; Gender:
64% women; Years of education:M = 15.21, SD = 2.94) and 101
met the standard criteria for the initial MCI group (Age: M =
73.75, SD = 5.55; Gender: 59.4% women; Years of education:
M = 14.52, SD = 3.08). The second research question required
two-wave longitudinal data. At W2, n = 218 participants (of
the 237) returned for testing (return rate = 92%). We then
excluded n = 1 for missing scores on the cognitive status clas-
sification measures (n = 217). With two baseline status groups
there were four possible two-wave status stability classifications.
For the longitudinal analysis, we focused on the conceptually
and clinically three most pertinent stability groups. First, the
stable NIC (NIC-to-NIC: n = 101; Age M = 73.23, SD = 5.28;
Gender: 61.4% women; Years of Education M = 15.55, SD =
2.96) group was our benchmark (non-demented aging) com-
parison. Second, the corresponding declining NIC (NIC-to-MCI:
n = 25; Age M = 72.64, SD = 5.30; Gender: 72% women; Years
of Education: M = 13.92, SD = 2.12) group represented status
transition (emerging conversion, early MCI) over two waves.
Third, the stable MCI (MCI-to-MCI: n = 68; Age: M = 73.50,
SD = 5.40; Gender: 55.9% women; Years of Education: M =
14.32, SD = 3.00) group represented continuing and chronic
MCI status. Regarding the fourth (or “reversion;” Koepsell and
Monsell, 2012) group, although previously observed in the lit-
erature (Palmer et al., 2002; Abner et al., 2012; Brodaty et al.,
2013), we had no theory-based prediction for it. Therefore, for
this and statistical reasons, we classified the MCI-to-NIC group
(n = 23; Age M = 73.83, SD = 5.57; Gender: 65.2% women;
Years of Education: M = 14.30, SD = 3.13) but did not include
it in the analyses.
COGNITIVE STATUS CLASSIFICATION PROCEDURE
We used a standard and fully objective (non-clinical and non-
subtyped), four-step classification procedure, applying it inde-
pendently at W1 and W2. The systematic procedure has been
used in previous VLS studies and is consistent with other research
and consensus reports (e.g., Ritchie et al., 2001; Winblad et al.,
2004; Dixon et al., 2007; de Frias et al., 2009; Albert et al., 2011;
Dolcos et al., 2012; Dixon and de Frias, 2014). The participants
represented the complete subset available for genotyping of a
somewhat larger VLS study of MCI (Dolcos et al., 2012). The
larger sample was from the same population base and thus was
used to optimize normative classification for the present sub-
set (see Dolcos et al., 2012; n = 416 at W1; n = 301 W1-W2
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returnees). The VLS MCI classification procedure emphasized
objective assessments of cohort-relative performance on a set of
five cognitive reference measures, as evaluated in four successive
steps. The first step is to stratify the sample by both age (64–73
and 74–95) and education (0–12 or 13+ years). The second step
places each individual into one of four resulting age x education
cells. The third step is to calculate mean and distributional char-
acteristics for each of five cognitive reference measures. The five
psychometrically sound tasks (e.g., Hultsch et al., 1998) represent
the theoretical domains of perceptual speed, inductive reason-
ing, episodic memory, verbal fluency, and semantic memory. In
the fourth step, these means and variability are used for within-
sample norms and cognitive status classification. Specifically, we
used a moderate criterion whereby participants were classified as
MCI if they scored one or more standard deviations (SD) below
their own age x education group means on one or more of the
five cognitive reference tasks. The one SD criterion was previ-
ously established and represented an approach that provided a
sensitive degree of differentiation appropriate to the present goal
of detecting early signs of cognitive impairment (Ritchie et al.,
2001; Dixon et al., 2007; de Frias et al., 2009; Dolcos et al., 2012).
See description above and Table 1 for the results of the status
classification.
COGNITIVE REFERENCE MEASURES
The five standard measures from the cognitive reference bat-
tery (e.g., Dixon et al., 2007; Dolcos et al., 2012) are widely
available and documented with older adults. The psychomet-
ric properties and administrative details are documented and
acceptable according to conventional standards (e.g., Hultsch
et al., 1998). Performance at W1 for each subgroup is shown in
Table 1.
Perceptual speed
Perceptual processing speed was assessed with the Wechsler Adult
Intelligence Scale—Revised Digit Symbol Substitution (DSS) task
(Wechsler, 1981). Psychometric characteristics of the DSS are
well-established in aging and other populations (e.g., MacDonald
et al., 2003). The number of correctly completed items was used
as the final outcome.
Inductive reasoning
Inductive reasoning was assessed with the Letter Series test
(Thurstone, 1962), frequently used with older adults. Participants
were presented with 20 strings of letters forming a distinct
pattern. The outcome was the total number correct.
Episodic memory
The VLS word recall task, consisting of immediate free recall of
two lists of 30 English words selected from the total set of six
equivalent lists (Dixon et al., 2004), was used. Each list consisted
of six words from each of five taxonomic categories (e.g., birds,
flowers), typed on a single page in unblocked order. The outcome
was the average number of correctly recalled words.
Verbal fluency
We used the Controlled Associations test (synonyms) from the
Educational Testing Service (ETS) kit of factor-referenced cogni-
tive tests (Ekstrom et al., 1976). The outcome measure was the
total number of correct synonyms.
Table 1 | Sample demographics at wave 1 by initial cognitive status at wave 1 and cognitive status stability (waves 1–2).
Wave 1 NIC MCI Wave 12 NIC-NIC NIC-MCI MCI-MCI
N
W1 136 101 101 25 6S
AGE
W1 73.12 (5.25) 73.75 (5.55) 73.23 (5.28) 72.64 (5.30) 73.50 (5.40)
GENDER (W)
W1 64% 59.4% 61.4% 72% 55.9%
EDUCATION
W1 15.21 (2.94) 14.52 (3.08) 15.55 (2.96) 13.92 (2.12) 14.32 (3.00)
PERCEPTUAL SPEED
W1 50.95 (9.36) 44.15 (10.59) 51.58 (9.89) 49.52 (7.69) 45.19 (10.10)
INDUCTIVE REASONING
W1 12.99 (3.38) 9.31 (4.83) 13.34 (3.45) 12.00 (2.86) 8.74 (4.79)
EPISODIC MEMORY
W1 20.01 (2.94) 15.95 (5.99) 20.18 (3.07) 19.06 (2.37) 15.43 (4.12)
VERBAL FLUENCY
Wl 17.26 (5.64) 12.15 (5.99) 17.98 (5.59) 14.72 (5.00) 11.01 (6.26)
VOCABULARY
W1 46.26 (3.90) 42.14 (5.56) 46.41 (3.78) 45.48 (4.10) 41.32 (5.74)
W1, Wave 1; W2, Wave 2; Wave 12, Wave 1–Wave 2; N, Sample size; NIC, Not impaired controls; MCI, Mild cognitive impairment; Age and education data presented
as Average (Standard Deviation): Cognitive domains represent the 5 cognitive reference measures used for cognitive status classification: For the two-wave groups
(Wave 12), the data refer to baseline (W1) values.
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Vocabulary
The 54-item recognition, multiple-choice vocabulary test was
composed by concatenating three 18-item tests from the ETS
kit of factor referenced cognitive tests (Ekstrom et al., 1976).
The total number of correct items representing the vocabulary
score.
DNA EXTRACTION AND GENOTYPING
Following completion of the last testing session, saliva was col-
lected according to standard procedures from Oragene DNA
Genotek and stored at room temperature in Oragene® disks
until DNA extraction. DNA was manually extracted from 0.8ml
of saliva sample mix using the manufacturer’s protocol with
adjusted reagent volumes. Briefly, samples were incubated for
2.5 h at 50◦C after inversion. Samples were transferred to a cen-
trifuge tube and mixed with Oragene® purifier, incubated on ice
for 10min, then centrifuged at 15,000 g for 5min to pellet the
denatured protein. The supernatant was transferred to a new
tube and DNA was precipitated by adding an equal volume of
100% ethanol. The DNA pellet was washed with 70% ethanol,
dried, and re-suspended with 10mM Tris, pH 8.0; 1mM EDTA
buffer. DNAwas incubated at 50◦C for 1 h with occasional vortex-
ing followed by incubation at 4◦C overnight to ensure complete
rehydration before quantification using a NanoDrop® ND-1000
Spectrophotometer (Wilmington, DE).
Genotyping was carried out with a Polymerase Chain Reaction
(PCR) and Restricted Fragment Length Polymorphism (RFLP)
strategy to analyze the allele status for APOE (determined by
the combination of the Single Nucleotide Polymorphisms (SNPs)
rs429358 and rs7412), BDNF (rs6265), and COMT (rs4680).
SNP-containing PCR fragments were amplified in 25 ul of 1X
PCR reaction mix containing 25 ng genomic DNA, 12.5 pmol
of each specific primer (APOE Forward: 5′-GGCACGGCTGT
CCAAGGA-3′. APOE Reverse: 5′-GCCCCGGCCTGGTACACT
GCC-3′; BDNF Forward: 5′-AAACATCCGAGGACAAGGTG-3′.
BDNF Reverse: 5′-AGAAGAGGAGGCTCCAAAGG-3′; COMT
Forward: 5′-GGGCCTACTGTGGCTACTCA-3′. COMT Reverse:
5′-CCCTTTTTCCAGGTCTGACA-3′), 6.25 nmol of each dNTP,
1.25U Taq DNA polymerase (New England Biolabs, NEB),
1.5mM MgCl2 and 10% dimethylsulfoxide (DMSO). Reactions
were set up in 96-well plates using the QIAgility robotic system
(QIAgen). Specific amplicons were amplified using a program
consisting of: denaturation step at 95◦C for 2min, 40 cycles at
94◦C for 30 s, 56◦C for 30 s, and 72◦C for 1min, and then a
final extension at 72◦C for 7min. RFLP analysis was performed
after digestion of the PCR amplicons with restriction enzymes
(all from NEB) as follows: (a) APOE, for 16 h at 37◦C with HhaI,
and (b) BDNF and COMT for 16 h at 37◦C with NlaIII. RFLP
analysis was then performed on a high resolution DNA screening
cartridge on a QIAxcel capillary electrophoresis system (QIAgen)
with the protocol OL700. The migration of the restriction frag-
ments on 10 or 15% acrylamide gels for each SNP confirmed the
analysis.
DATA ANALYSIS
All statistical analyses were performed using SPSS version
17.0 statistical software. For the W1 analysis, we used logistic
regression to examine whether APOE, COMT, and BDNF poly-
morphisms were associated with initial cognitive group status
(NIC vs. MCI). For the longitudinal analyses, we used multino-
mial logistic regression to examine whether APOE, BDNF, and
COMT polymorphisms were associated with stability of cog-
nitive functioning (stable NIC-to-NIC, unstable NIC-to-MCI,
and stable MCI-to-MCI) across the retest interval. In addi-
tion to standard independent candidate gene analyses, we also
tested whether genetic risk would be magnified in the con-
text of risk alleles combined across two cognitive-related genes.
Because of limited cell sizes and power (in some instances)
we followed the procedure of computing the two-way interac-
tions, each of which compared the presence of both risk alle-
les/genotypes with all other possible genetic combinations for
those particular genes. The two-way interactions between the test
alleles (APOE ε4+, COMT G/G, and BDNF A/A) were com-
puted, as referenced by the three control alleles (APOE ε4−,
COMT A/A, and BDNF G/G). We assessed whether these genetic
risk factors in two-way combinations (only) increased the risk
of (a) MCI classification at baseline and (b) two-wave conver-
sion to MCI (NIC-to-MCI) or MCI chronicity (MCI-to-MCI).
Given our a priori directional hypotheses, we employed one-
tailed tests. Post-hoc logistic regression power analyses (GPower
3.1) indicate that the present study has (a) sufficient power
to detect independent (genotype) effects (baseline single-factor
power, M = 0.90; longitudinal single-factor power, M = 0.80),
but (b) lower power to detect two-way (BDNF, COMT, APOE)
interactions (baseline power, M = 0.62; longitudinal power,
M = 0.42). We reported our interactive analyses cautiously,
given few prior relevant reports using these polymorphisms
for MCI.
RESULTS
We first report the initial allelic frequency results. For the two
research questions age and education were entered into all anal-
yses as covariates. Analyses without education as a covariate
(Luciano et al., 2010) showed identical patterns.
GENOTYPE AND ALLELIC FREQUENCIES
Consistent with literature indicating that APOE, BDNF, and
COMT polymorphisms may be associated with lower levels of
cognitive functioning in older adults (Bruder et al., 2005; Payton,
2009; Cathomas et al., 2010; Wisdom et al., 2011; Laukka et al.,
2013), we informally expected that these genetic polymorphisms
would show differential frequencies between the two cognitive
status groups at baseline and among the four cognitive status sta-
bility groups (Brainerd et al., 2011). As can be seen in Table 1,
participant demographics did not differ appreciably between
waves or groups. Genotype and allele frequencies at baseline and
at follow-up are reported in Table 2 (W1) and Table 3 (W1-W2)
for each cognitive status and stability group. As seen in these
tables, the distributions are reasonable and generally expected.
For all three polymorphisms the W1 sample distributions were
in Hardy-Weinberg equilibrium: (a) COMT (χ2 = 0.06, n.s.),
(b) BDNF (χ2 = 0.09, n.s.), and (c) APOE (calculated in three
groups rendered in terms of presence/absence of the ε4 allele)
(χ2 = 0.02, n.s.).
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Table 2 | Frequency of APOE, COMT and BDNF genotypes and alleles
at wave 1, as stratified by cognitive status.
Variable NIC MCI
N 136 101
APOE
No ε4 106 (77.9) 69 (68.3)
≥ 1 ε4 30 (22.1) 32 (31.7)
COMT
A/A 31 (22.8) 20 (19.8)
A/G 80 (58.8) 53 (52.5)
G/G 25 (18.4) 28 (27.7)
BDNF
A/A 8 (5.9) 4 (4)
A/G 36 (26.5) 34 (33.7)
G/G 92 (67.6) 63 (62.4)
APOE, Apolipoprotein E; ε4, APOE epsilon 4 allele; BDNF, Brain derived neu-
rotrophic factor; COMT, Catechol O-methyltransferase; G, Guanine, Valine amino
acid; A, Adenine, Methionine amino acid; N, Sample size; NIC, Not Impaired
Controls; MCI, Mild Cognitive Impairment; ≥1 ε4, the presence of at least 1
APOE ε4 allele; data presented as Frequency (Percentage).
GENETIC MARKERS OF BASELINE COGNITIVE STATUS
We used binary logistic regression to examine baseline group dif-
ferences in (a) cognitive status (NIC vs. MCI) and (b) APOE,
COMT and BDNF genotype. As reported in Table 4, the pres-
ence of at least one APOE ε4 allele was associated with a 1.65-fold
higher likelihood of MCI classification at baseline compared to
NIC [p = 0.047 (1-tailed)]. The COMT A/G (Met/Val) or COMT
G/G (homozygous Val) genotypes were not associated with an
increased risk of MCI classification at baseline compared to the
COMT A/A (homozygous Met) genotype. Similarly, the BDNF
A/G or BDNF A/A (homozygous Met) genotypes were not asso-
ciated with an increased risk of MCI classification at baseline
compared to the BDNF G/G (homozygous Val) genotype. The 2-
way interactions between APOE, COMT, and BDNF revealed no
significant increased risk of MCI classification at baseline for the
interaction terms.
GENETIC MARKERS OF TWO-WAVE STABILITY OF COGNITIVE STATUS
The association between APOE, COMT, and BDNF genotype
with cognitive status stability across the W1-W2 retest interval
was examined using multinomial logistic regression. Consistent
with previous reports which indicate that APOE, BDNF, and
COMT polymorphisms may be implicated in cognitive decline
(Bruder et al., 2005; Blom et al., 2009; Hashimoto et al., 2009;
Schiepers et al., 2012), we expected that APOE, BDNF, and
COMT polymorphisms would be associated with NIC instabil-
ity (i.e., emerging impairment, NIC-to-MCI) and MCI stability
(i.e., impairment chronicity, MCI-to-MCI) across the retest inter-
val. As reported in Table 4, the presence of at least one APOE
ε4 allele was associated with a 1.82-fold higher likelihood of
MCI-to-MCI stability (chronicity) over time compared to a sta-
ble NIC-to-NIC classification (p = 0.050, 1-tailed). Although
APOE ε4 was not associated with NIC-to-MCI decline over
time, a dose-response effect for the ε4 allele was noted between
Table 3 | Frequency of APOE, COMT and BDNF genotypes and alleles
across the W1-W2 retest interval, as stratified by cognitive status
stability group.
Variable Wave NIC-NIC NIC-MCI MCI-MCI
N
W2 101 25 68
APOE
no ε4 W2 80 (79.2) 18 (72) 46 (67.6)
≥1 ε4 W2 21 (20.8) 7 (28) 22 (32.4)
COMT
A/A W2 27 (26.7) 4 (16) 14 (20.6)
A/G W2 59 (58.4) 13 (52) 35 (51.5)
G/G W2 15 (14.9) 8 (32) 19 (27.9)
BDNF
A/A W2 5 (5) 2 (8) 3 (4.4)
A/G W2 29 (28.7) 4 (16) 20 (29.4)
G/G W2 67 (66.3) 19 (76) 45 (66.2)
APOE, Apolipoprotein E; ε4, APOE epsilon 4 allele; BDNF, Brain Derived
Neurotrophic Factor; COMT, Catechol O-methyltransferase; G, Guanine, Valine
amino acid; A, Adenine, Methionine amino acid; W1, Wave 1; W2, Wave 2; N,
Sample size; NIC, Not Impaired Controls; MCI, Mild Cognitive Impairment; ≥1
ε4, the presence of at least 1 APOE ε4 allele; data presented as Frequency
(Percentage).
the 2-wave cognitive stability groups (i.e., NIC-to-NIC, MCI-
to-MCI; Table 4). Although the COMT G/G (homozygous Val)
genotype was not associated with baseline status, it was asso-
ciated with both a 3.94-fold higher likelihood of NIC-to-MCI
decline and a 2.60-fold higher likelihood of MCI-to-MCI stabil-
ity (chronicity) over time, as compared to the stable NIC-to-NIC
classification group (p = 0.027 and 0.025, respectively, 1-tailed).
COMT A/G was not associated with either two-wave profile.
The BDNF A/A (homozygous Met) or A/G genotypes were not
associated with NIC-to-MCI conversion or with MCI-to-MCI
stability over time. The 2-way interactions between APOE, BDNF,
and COMT did not confer any significant associations with the
stability and status groups.
DISCUSSION
We examined risk of objectively assessed MCI (distinguished
from non-demented aging) as associated with risk alleles of three
relevant polymorphisms. Group membership in three MCI pro-
files was examined: (a) baseline (W1), with NIC compared with
MCI, (b) two-wave stability of MCI status, reflecting chronic and
stable condition (i.e., MCI-to-MCI), and (c) two-wave decline in
NIC status, reflecting early and emerging conversion to classifi-
able impairment (i.e., NIC-to-MCI). This study both replicates
and extends recent single-wave MCI assessments by including (a)
two-wave independent follow-up classifications, (b) tests of the
typical APOE genetic variant plus two additional variants, and (c)
assessments of two-wave patterns reflecting impaired chronicity
and emerging conversion.
We discuss the results as organized by the three genetic poly-
morphisms. First, APOE was expected to be a significant marker.
The ε4 variant is the best known genetic risk factor for sporadic
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Table 4 | Statistical results relating genetic risk factors to cognitive status and stability for APOE, COMT and BDNF.
Predictor Wave Status/Stability Genotype P OR 95% CI P
APOE W1 MCI ≥1 ε4 0.503 1.653 0.918–2.976 0.047
W12 NIC-MCI ≥1 ε4 0.383 1.467* 0.533–4.038 0.458
W12 MCI-MCI ≥1 ε4 0.598 1.819* 0.892–3.710 0.050
COMT W1 MCI A/G 0.036 1.037 0.534–2.013 0.458
W1 MCI G/G 0.560 1.750 0.798–3.840 0.082
W12 NIC-MCI A/G 0.434 1.543 0.455–5.235 0.243
W12 NIC-MCI G/G 1.371 3.939 0.976–15.900 0.027
W12 MCI-MCI A/G 0.160 1.173 0.540–2.551 0.344
W12 MCI-MCI G/G 0.956 2.601 0.998–6.775 0.025
BDNF W1 MCI A/G 0.328 1.388 0.783–2.461 0.131
W1 MCI A/A −0.164 0.848 0.239–3.014 0.400
W12 NIC-MCI A/G −0.673 0.510 0.157–1.661 0.132
W12 NIC-MCI A/A 0.278 1.321 0.220–7.930 0.381
W12 MCI-MCI A/G 0.048 1.041 0.523–2.102 0.447
W12 MCI-MCI A/A 0.782 1.018 0.220–4.718 0.491
APOE, Apolipoprotein E; ε4, APOE epsilon 4 allele; BDNF, Brain derived neurotrophic factor; β, co-efficient: COMT, Catechol O-methyltransferase; A, Adenosine
nucleotide, Methionine amino acid; G, Guanine nucleotide, Valine amino acid; N, sample size; NIC, Not Impaired Controls; MCI, Mild Cognitive Impairment; OR,
odds ratio: W1, Wave 1; W12, Wave 1–Wave 2; ≥1 ε4, the presence of at least 1 APOE s4 allele; for APOE analyses, the presence of ≥1 ε4 was compared to the
absence of ε4 (reference group): for BDNF analyses, BDNF A/G and A/A were compared to BDNF G/G (reference group) separately; for COMT analyses, COMT
G/G and A/G were compared to COMT A/A (reference group) separately; the NIC group was the reference group for W1, whereas the stable NIC group was the
reference group for W1-W2 analyses; p values are all presented as one-tailed; stars indicate dose response findings.
AD (Albert et al., 2011; Harris and Deary, 2011) and has been
implicated in candidate gene studies for normal cognitive decre-
ments (e.g., Small et al., 2004; Kozauer et al., 2008; Liu et al., 2010;
Izaks et al., 2011; Wisdom et al., 2011; Davies et al., 2014) and
mild cognitive impairment (Brainerd et al., 2011; Reinvang et al.,
2013). Brainerd and colleagues reported that the ε4 variant was
more represented in older adults classified as MCI than in a non-
demented comparison group. Our results are consistent with (and
extend) these findings. Using fully objective classification proce-
dures, we observed that the presence of at least one APOE ε4
allele conferred increased risk of MCI classification (a) at baseline
and (b) for stability (chronicity) over the two-wave interval. We
interpret the latter as evidence both for the stability of our MCI
classifications and for their usefulness for detecting preclinical
decrements early in cognitive aging. Notably, we use the objective,
multi-dimensional cognitive reference battery approach to cap-
ture mild disorder that (a) may be transient or variable among
some such early cases of impairment (Koepsell and Monsell,
2012), (b) may even be reflected by modest deficits (i.e., 1 SD)
in a single fundamental domain (Dolcos et al., 2012), and (c) do
not reflect the potential that differential domain deficits may be
indicative across waves and subtypes (Brodaty et al., 2013). For
this reason, the classification battery represents five complemen-
tary domains of basic cognitive resources. Within the objective
VLS classification approach, this is the first evidence regard-
ing genetic associations, but it has previously pointed to MCI
associations with executive functioning (de Frias et al., 2009),
memory (Dixon and de Frias, 2014), neurocognitive inconsis-
tency (Dixon et al., 2007), functional biomarkers (Dolcos et al.,
2012), and molecular-level metabolomics markers (Zheng et al.,
2012). Future progress will be achieved when researchers are able
to assemble and analyze multifaceted sets of markers relevant
to early MCI transitions, stability, and outcomes (Fotuhi et al.,
2009; Anstey, 2014). Although we present two-wave data, wemust
await future waves to discover the extent to which MCI-to-MCI
chronicity is also probabilistically linked to eventual AD. For now,
the predictions of surrogate outcomes (MCI baseline status and
4-year stability or chronicity) are promising results.
Second, the COMT G variant (including Val-Val and Val-Met)
has been identified as a risk factor for cognitive deficits with
normal aging, given the association with the degradation of cat-
echolamine neurotransmitters (such as dopamine) (Savitz et al.,
2006). However, previous results of candidate gene studies have
revealed promising but inconsistent association patterns (Barnett
et al., 2008;Wishart et al., 2011; Sapkota et al., 2014) andMCI sta-
tus (Martinez et al., 2009; Yarnell et al., 2014). Had we only exam-
ined concurrent data we would have reported no MCI-related
associations. Instead, the COMT variant emerged as a significant
marker of MCI chronicity and transition in the two-wave data.
This may be due to its sensitivity to early cognitive aging dis-
orders in performances represented by the present broad-based
neurocognitive reference battery, especially among older adults
who are transitioning (NIC-to-MCI) or chronically MCI. These
dynamic groups may present more homogeneous MCI-related
phenotypes than the larger baseline source group. The extent to
which the COMT G variant (homozygous G/G) was involved
in predicting status chronicity and conversion was novel and
promising. Together with recent work showing promising syn-
ergistic effects (Martinez et al., 2009; Lanni et al., 2012), COMT
may deserve additional attention inMCI, especially in the context
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of APOE, longitudinal follow-ups, and phenotypes reflecting its
neurobiological influence. Perhaps with objective but sensitive
assessment procedures, COMT may prove to be a candidate
genetic susceptibility marker of early cognitive changes associated
with neurobiological disruptions that may be secondary or pre-
liminary to AD-related neuropathology. At present, the absence
of COMT from the pantheon of MCI-related genes may be asso-
ciated with the fact that, by the time individuals convert to
dementia, the genetic associations are overwhelmed by APOE and
its direct connection to amyloid beta deposition. Future research
can investigate whether the apparent separate contributions of
APOE and COMT to MCI status and change continue to be com-
plementary or whether a gene-related would produce synergistic
vulnerability (Lindenberger et al., 2008; McFall et al., 2014).
Third, the other polymorphism (BDNF) was not statisti-
cally associated with the targeted outcomes. In general, BDNF-
cognition associations are inconsistently observed and difficult to
interpret (Mandelman andGrigorenko, 2012). In addition, BDNF
associations are rarely tested as predictors of clinical or cognitive
status or neurodegenerative changes (cf. Forlenza et al., 2010).
The mechanisms through which BDNF may affect neurocogni-
tive performance are proposed (Savitz et al., 2006; Harris and
Deary, 2011) but their relevance to non-normal cognitive status
has not been firmly established. As an MCI predictor, BDNF may
be less relevant for early classification (as in this study) than for
later cognitive impairment (Forlenza et al., 2010). We included
BDNF for two reasons: (a) it could have been related to objective
cognitive status as we assess it (via performance on a reference
battery including memory and speed markers) and (b) it could
have appeared as an associate of cognitive status in the role of
interacting influence.
Overall, the findings of this study reveal several interest-
ing independent and complementary genetic associations with
non-demented aging and MCI status, including initial, transi-
tioning, and chronic profiles. However, several limitations should
be acknowledged. First, not all VLS data were available for the
present study, as the first phase of the genetics initiative occurred
only recently, thus limiting the overall and (especially) clinical
group sample sizes. Further genotyping and follow-up waves are
planned. Second, our MCI classification procedures are derived
from consensus statements (e.g., Albert et al., 2011) and standard-
ized procedures (e.g., Dixon et al., 2007). They do not include
several characteristics sometimes observed in the literature: (a)
clinical judgment or personal evaluations, (b) differentiation
into subtypes of MCI, or (c) criteria emphasizing established or
severe pre-dementia cases (e.g., Winblad et al., 2004; Petersen
and Knopman, 2006; Dolcos et al., 2012). Instead, we empha-
sized (a) replicable and transferable classification (i.e., objective
procedures may be translated into multiple research and clini-
cal settings), (b) overall MCI classification based on deficits in
multiple possible basic domains as based on the assumption that
early or emergent cases may not (yet) be consolidated into sub-
types, and (c) use of moderate criteria (i.e., 1 SD below the
appropriate group mean) so that early cases may be identified,
at the risk of some false positives. In the VLS, transitions into
MCI and dementia are slowly emerging as the VLS itself “ages.”
Emergence of differential subtypes, etiology, and severities will be
followed, as they could modify future interpretations. Third, we
focus on predictors of emergence, stability, and early transitions
in MCI. Extending research to predictors of later transitions (e.g.,
MCI-dementia) will require larger samples of well-diagnosed
dementia patients. Other researchers are also embracing the chal-
lenge of investigating characteristics and markers of early MCI
(e.g., Kryscio et al., 2006; Anstey et al., 2013; Risacher et al., 2013)
using status change or stability as surrogate outcomes.
Fourth, the sample size of the present study was limited
because the design required participation in two longitudinal
waves. Relevant published studies vary in sample size, age ranges,
and availability of longitudinal intervals (Caselli et al., 2007, 2014;
Martinez et al., 2009; Forlenza et al., 2010; Brodaty et al., 2013;
Risacher et al., 2013). We reported a limitation in the power to
detect gene x gene interactions. However, the fact that we did not
observe significant synergistic interactions may also be related to
other fundamental aspects of the emergence and progression of
relatively early MCI in aging: (a) these processes may not have
been sufficiently advanced to “recruit” or “require” such interac-
tional contributions, (b) these genetic variants may not be those
that are involved in interactional predictions of MCI, and (c)
more diverse, more select, more severe, or etiologically purer sam-
ples might extend the present results. Much larger studies may be
better powered for interaction analyses, but this can balanced if
they lack the nuanced or valid cognitive measures or have subop-
timal intervals. Therefore, we do not rule out the potential role of
gene x gene interactions in predicting the phenomena we address
in this study. Fifth, there are a number of unmeasured factors in
any study of normal cognitive aging or emergent and longitudi-
nal MCI phenomena (e.g., Fotuhi et al., 2009; Albert et al., 2011;
Woodard et al., 2012). One possible avenue for future research
includes investigation of multiple AD-related markers (Risacher
et al., 2013) or gene x environment (e.g., health; Anstey, 2014;
McFall et al., 2014) effects. Sixth, we studied only three genetic
variants, and others could be investigated in the prediction of
MCI status, stability, and transitions. However, many candidate
gene studies of MCI include only one variant (typically APOE).
We recommend the careful selection of additional polymor-
phisms based on known underlying neurobiological mechanisms
related to MCI.
In sum, we observed two sets of independent and comple-
mentary associations with theoretically and clinically relevant
phenomena of early cognitive impairment in aging. Both early
and more advanced cognitive impairment is likely the result of
a complex, life-long series of interactions among various genetic
susceptibility and environmental risk factors. Regarding genetic
polymorphisms, both APOE and COMT hold promise for future
complex and dynamic analyses of the short- and long-term pro-
cesses through which some normally aging individuals begin
transitioning into preclinical impairment.
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